Demo Demo2Profile
Demo Demo2Profile is an expert in Oncology at Baylor Scott & White Health (United States). As of April 2023, ScienceLeadR ranks Demo Demo2Profile in the top 1% of experts worldwide for Sarcoma, Chondrosarcoma and Synovitis. Demo Demo2Profile has authored 920 publications, the most recent in 2023, and is an investigator in 103 clinical trials, 6 of them ongoing. SLR score: 6,992 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Public Health - Therapeutics - Surgery
Main Topics
Publications and Clinical Studies
Profile data updated on
Short Biography
Dr. John Smith, MD
Dr. John Smith is a board-certified cardiologist with over 15 years of experience in diagnosing and treating cardiovascular diseases. A graduate of Harvard Medical School, he completed his specialization in interventional cardiology. Passionate about medical innovation, Dr. Smith frequently speaks at international conferences and has authored numerous articles in leading medical journals. Known for his compassionate care and patient-centered approach, he is dedicated to helping his patients achieve optimal heart health and improved quality of life.
Organizations
Career arc: 1995 - 2023
Number : 920
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
Clinical Studies 103
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
6 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| HDM201 and Pazopanib in Patients With P53 Wild type Advanced Metastatic Soft Tissue Sarcomas NCT05180695 — safety, pharmaceutical preparations, disease progression, sarcoma, genes, p53, response evaluation criteria in solid tumors, tissues | Phase 1/Phase 2 | Active not recruiting | 2022 |
| Study of Vimseltinib for Tenosynovial Giant Cell Tumor NCT05059262 — cells, genes, dcc, safety, giant cell tumors, giant cell tumor of tendon sheath, neoplasms, double-blind method, tendons, giant cells, synovitis, pigmented villonodular, therapeutics, synovitis | Phase 3 | Active not recruiting | 2021 |
| Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist Ten) NCT05009927 — mesylates, gastrointestinal stromal tumors, neoplasms, tablets, maintenance, protein-tyrosine kinases, tyrosine, therapeutics, imatinib mesylate, mutation | Phase 2 | Recruiting | 2022 |
| Study of INBRX 109 in Conventional Chondrosarcoma NCT04950075 — cells, chondrosarcoma, apoptosis, cell death | Phase 2 | Active not recruiting | 2021 |
| Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING) NCT04921553 — registries, genes, quality of life, data collection, proto-oncogene proteins c-sis, neoplasms, gene rearrangement, gene fusion, therapeutics, mutation | N/A | Recruiting | 2021 |
LeadR Networks
Main global connection map